Centene stock forecast
Centene's weighted forecast reaches $75.51 by October 2029, a 10% total return including dividends. It hinges on Centene repairing underwriting and making the earnings recovery durable.
Where could Centene's shares be by 2029?
The forecast places the price at $48.80 in October 2027, a 29% decline including dividends. It reaches $75.51 in October 2029. The bear case carries 30%, the base case 55%, and the bull case 15%.
The weighted price is $48.80 in October 2027 and $61.80 in October 2028. Those outcomes represent declines of 29% and 10% with dividends included. The October 2029 weighted price is $75.51, a 10% total return. Against today’s $68.63, the October 2029 range runs from $22.85 in the bear case to $155.57 in the bull case.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 30 % | 18.05 (-74 %) | 19.91 (-71 %) | 22.85 (-67 %) |
| Base | 55 % | 54.41 (-21 %) | 68.57 (-0 %) | 82.40 (+20 %) |
| Bull | 15 % | 89.74 (+31 %) | 120.75 (+76 %) | 155.57 (+127 %) |
| Weighted | 100 % | 48.80 (-29 %) | 61.80 (-10 %) | 75.51 (+10 %) |
What has to go right for Centene, and what could go wrong?
The base case starts from the $175,000M 2026 premium and service revenue midpoint and assumes moderate growth with margins recovering from 1.35% to 1.60%. That produces the table’s earnings path. The bear case uses slower revenue growth and margins of 0.6% to 0.8%, reflecting medical-cost pressure and weaker Marketplace risk. The bull case reaches margins of 1.7% to 2.2%, supported by better pricing, claims management and Medicare Advantage approaching break-even. The base is anchored by Q2 HBR improvement and the $4.80 floor, but excludes the roughly $0.50 per-share settlement benefit that management says will not recur in 2027.
The bull case would require Medicaid rates to exceed medical trend, profitable Ambetter retention and sustained HBR improvement. Earlier Medicare Advantage break-even and resumed buybacks would provide the strongest confirmation.
How much cash does Centene really make?
Operating cash flow fell to $154 million in 2024 from $8,053 million in 2023. It recovered to $5,088 million in 2025, helped by better pharmacy-rebate timing and higher claims liabilities. After $767 million of capital spending, the arithmetic remainder was $4,321 million, but it was not freely distributable parent cash.
What does an investor pay for Centene today?
| Today (Oct 19, 2026) | |
|---|---|
| Share price | 68.63 |
| Market value (calculated) | 33,902.88 |
| P/E, last 12 months (calculated) | not meaningful |
| P/E on core earnings, last 12 months (calculated) | 13.2x |
| P/E, next 12 months (calculated) | 13.0x |
| Price to book (calculated) | 1.5x |
What this means. Centene's own ongoing-profit count shows a profit, while the standard count shows a loss, so the ordinary price-to-earnings ratio cannot be used and the adjusted ratio is 13.2.